Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Cancer Therapeutics
  • View item
  • Home
  • ICR Divisions
  • Cancer Therapeutics
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Development of molecularly targeted agents and immunotherapies in small cell lung cancer.

Thumbnail
View/Open
Accepted version (1.043Mb)
Date
2016-06
ICR Author
Sharp, Adam
O'Brien, Mary
Yap, Timothy
Popat, Sanjay
Author
Sharp, A
Bhosle, J
Abdelraouf, F
Popat, S
O'Brien, M
Yap, TA
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
Small cell lung cancer (SCLC) is a smoking-induced malignancy with multiple toxin-associated mutations, which accounts for 15% of all lung cancers. It remains a clinical challenge with a rapid doubling time, early dissemination and poor prognosis. Despite multiple clinical trials in SCLC, platinum-based chemotherapy remains the mainstay of treatment in the first line advanced disease setting; good initial responses are nevertheless inevitably followed by disease relapse and survival ultimately remains poor. There are currently no molecularly targeted agents licenced for use in SCLC. Advances in sequencing the cancer genome and other high-throughput profiling technologies have identified aberrant pathways and mechanisms implicated in SCLC development and progression. Novel anti-tumour therapeutics that impact these putative targets are now being developed and investigated in SCLC. In this review, we discuss novel anti-tumour agents assessed in SCLC with reference to the complex molecular mechanisms implicated in SCLC development and progression. We focus on novel DNA damage response inhibitors, immune checkpoint modulators and antibody-drug conjugates that have shown promise in SCLC, and which may potentially transform treatment strategies in this disease. Finally, we envision the future management of SCLC and propose a biomarker-driven translational treatment paradigm for SCLC that incorporates next generation sequencing studies with patient tumours, circulating plasma DNA and functional imaging. Such modern strategies have the potential to transform the management and improve patient outcomes in SCLC.
URI
https://repository.icr.ac.uk/handle/internal/465
DOI
https://doi.org/10.1016/j.ejca.2016.03.004
Collections
  • Cancer Therapeutics
  • Clinical Studies
Subject
Immune System
Humans
Lung Neoplasms
DNA Damage
Angiogenesis Inhibitors
Antineoplastic Agents
Immunotherapy
Cell Communication
Apoptosis
DNA Repair
Small Cell Lung Carcinoma
Drug Discovery
Molecular Targeted Therapy
Antibodies, Monoclonal, Humanized
Cell Cycle Checkpoints
Precision Medicine
Research team
Medicine Drug Development Unit (de Bono)
Thoracic Oncology
Translational Therapeutics
Treatment of thoracic tumours
Language
eng
Date accepted
2016-03-02
License start date
2016-06
Citation
European journal of cancer (Oxford, England : 1990), 2016, 60 pp. 26 - 39

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.